Diabetes/DKA Flashcards
Most severe adverse effect is lactic acidosis
metformin
MC side is hypoglycemia
= sulfonylureas
Recommended first line tx in Type 2 DM
= metformin
Not safe in settings of hepatic dysfunction or CHF?
TZDs
Should not be used in patients with elevated serum creatinine?
Metformin ( due to risk of lactic acidosis)
Should not be used in patients with cirrohsis or inflammatory bowel disease?
alpha glucosidase inhibitors
Not associated with weight gain?
Metformin, DPP-4 inhibitors, GLP-1 analogs
metabolized by liver, safe in renal disease pt?
TZDs (Pioglitazone, rosiglitazone)
Closes K+ channels on beta cells and ultimately increase insulin secretion
sulfonyureas (glimepiride, glipizide, glyburide)
Inhibits alpha glucosidase at intestinal brush border?
alpha glucosidase inhibitors
MOA: TZDs
increase insulin sensitivity in peripheral tissue. Binds to PPAR-γ nuclear transcription regulator.a
MOA: Metformin
Stimulate AMPK by decreasing glucose production and insulin resistance
PPAR gamma is found where? Function?
are found in skeletal muscle and adipose tissue ; they regulate FA storage and glucose metabolism ; they bind to the PPAr gamma transcription factor and activate it
Exenatide,
liraglutide (sc injection)
GLP-1 analogs
increase glucose-dependent insulin release, increase glucagon release, decrease gastric emptying, increase satiety.
GLP-1 analogs
GLP-1 analog MC SE?
pancreatitis
saxagliptin, sitagliptin
DPP-4 inhibitors
Inhibits DPP-4 enzyme that deactivates GLP-1, thereby increase glucose-dependent insulin release, decrease glucagon release, decrease gastric emptying, increase satiety.
DPP-4 inhibitors
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ( Canagliflozin, dapagliflozin)
Block reabsorption of glucose in PCT.
which increases renal glucose excretion
Not really popular among patients; avoid in patients with bowel issues
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ( Canagliflozin, dapagliflozin)
good for weight loss
GLP-1 agonists